Skip to main
CLDX
CLDX logo

Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics (CLDX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 41%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Celldex Therapeutics has demonstrated a strong financial position, ending the year with $725.3 million in cash, which is expected to support ongoing operations through 2027. The company's lead candidate, barzolvolimab, has shown significant potential in clinical trials, particularly in improving quality of life for patients with chronic spontaneous urticaria and related conditions. With promising data indicating rapid improvement in urticaria control and a potential to enhance dysphagia outcomes, Celldex is well-positioned to make strides in the immunotherapy market across various indications.

Bears say

The financial outlook for Celldex Therapeutics appears negative due to substantial risks associated with clinical development and the potential for failure in demonstrating the necessary efficacy and safety profiles required for regulatory approval. Additionally, the company faces significant challenges in execution that could limit commercial success and market potential, alongside a dependency on securing adequate funding to continue its drug development programs. Furthermore, the competitive landscape may further constrain the adoption of their innovative therapies, increasing the overall uncertainty surrounding the firm's future financial performance.

Celldex Therapeutics (CLDX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 41% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Celldex Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Celldex Therapeutics (CLDX) Forecast

Analysts have given Celldex Therapeutics (CLDX) a Buy based on their latest research and market trends.

According to 17 analysts, Celldex Therapeutics (CLDX) has a Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Celldex Therapeutics (CLDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.